Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Mehta, Rohini ^a,b   Neupane, Arpan ^a,b   Wang, Lei ^a,b   Goodman, Zachary ^a,c   Baranova, Ancha ^a,b   Younossi, Zobair M ^a,c  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Cytokines; Fibrosis; Inflammasomes; NAFLD; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; NACHT LRR AND PYD DOMAIN CONTAINING PROTEIN; NALP6 PORTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; UNCLASSIFIED DRUG; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; NLRP4 PROTEIN, HUMAN; NLRP6 PROTEIN, HUMAN; REPRESSOR PROTEIN; SIGNAL PEPTIDE;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER FIBROSIS; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PROTEIN EXPRESSION; UPREGULATION; COMPLICATION; DOWN REGULATION; FIBROSIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADIPOSE TISSUE; ADULT; CASPASE 1; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FIBROSIS; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; REPRESSOR PROTEINS; RNA, MESSENGER; UP-REGULATION;

EID: 84964312935     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-014-0208-8     Document Type: Article

References (45)

1. Flegal KM, Caroll MD: PRevalence of obesity and trends in the distribution of body mass index among us adults, 1999-2010. JAMA 2012, 307:491-497.
2. Kubes P, Mehal WZ: Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172.
3. Kono H, Rock KL: How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8:279-289.
4. Rock KL, Latz E, Ontiveros F, Kono H: The sterile inflammatory response. Annu Rev Immunol 2010, 28:321-342.
5. Maslanik T, Mahaffey L, Tannura K, Beninson L, Greenwood BN, Fleshner M: The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav Immun 2013, 28:54-62.
6. Wilmanski JM, Petnicki-Ocwieja T, Kobayashi KS: NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J Leukoc Biol 2008, 83:13-30.
7. Lupfer C, Kanneganti T-D: The expanding role of NLRs in antiviral immunity. Immunol Rev 2013, 255:13-24.
8. Martinon F, Gaide O, Ptrilli V, Mayor A, Tschopp J: NALP Inflammasomes: a central role in innate immunity. Semin Immunopathol 2007, 29:213-229.
9. Tschopp J, Martinon F, Burns K: NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003, 4:95-104.
10. Bryan NB, Dorfleutner A, Rojanasakul Y, Stehlik C: Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain. J Immunol 2009, 182:3173-3182.
11. Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998, 16:457-499.
12. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
13. Martinon F, Tschopp J: Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2006, 14:10-22.
14. Sims JE, Smith DE: The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 117:89-102.
15. Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, Caucheteux S, Ratner-Hurevich M, Berzofsky JA, Nir-Paz R, Paul WE: IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 2013, 210:491-502.
16. Dinarello CA: The interleukin-1 family: 10 years of discovery. FASEB J 1994, 8:1314-1325.
17. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001, 12:53-72.
18. Baranova A, Collantes R, Gowder SJ, Elariny H, Schlauch K, Younoszai A, King S, Randhawa M, Pusulury S, Alsheddi T, Ong JP, Martin LM, Chandhoke V, Younossi ZM: Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg 2005, 15:758-765.
19. Lago F, Dieguez C, Gmez-Reino J, Gualillo O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3:716-724.
20. Powell K: Obesity: the two faces of fat. Nature 2007, 447:525-527.
21. Gerner RR, Wieser V, Moschen AR, Tilg H: Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver1. Can J Physiol Pharmacol 2013, 91:867-872.
22. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z: Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53:1874-1882.
23. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL: Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012, 13:134.
24. Mehta R, Birerdinc A, Hossain N, Afendy A, Chandhoke V, Younossi Z, Baranova A: Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol 2010, 11:39.
25. Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
26. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
27. Benetti E, Chiazza F, Patel NSA, Collino M: The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediat Inflamm 2013, 2013:678627.
28. Szabo G, Csak T: Inflammasomes in liver diseases. J Hepatol 2012, 57:642-654.
29. Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R: Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. J Inflamm 2012, 9:49.
30. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez J-P, Shulman GI, Gordon JI, Hoffman HM, Flavell RA: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
31. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE: NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis. Hepatology 2014, 59(3):898-910.
32. Ponsuksili S, Brunner RM, Goldammer T, Khn C, Walz C, Chomdej S, Tesfaye D, Schellander K, Wimmers K, Schwerin M: Bovine NALP5, NALP8, andNALP9 genes: assignment to a QTL region and the expression in adult tissues, oocytes, and preimplantation embryos. Biol Reprod 2006, 74:577-584.
33. Zhang P, Dixon M, Zucchelli M, Hambiliki F, Levkov L, Hovatta O, Kere J: Expression analysis of the NLRP gene family suggests a role in human preimplantation development. PLoS ONE 2008, 3(7):e2755.
34. Baranova A, Tran TP, Afendy A, Wang L, Shamsaddini A, Mehta R, Chandhoke V, Birerdinc A, Younossi ZM: Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013, 11:133.
35. Baranova A, Tran TP, Birerdinc A, Younossi ZM: Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011, 33:801-814.
36. Reggio S, Pellegrinelli V, Clment K, Tordjman J: Fibrosis as a cause or a consequence of white adipose tissue inflammation in obesity. Curr Obes Rep 2013, 2:1-9.
37. Garca MC, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O, Horn M, Ahrn B, Enerback S, Ohlsson C, Wallenius V, Jansson J-O: Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 2006, 55:1205-1213.
38. Kotas ME, Jurczak MJ, Annicelli C, Gillum MP, Cline GW, Shulman GI, Medzhitov R: Role of caspase-1 in regulation of triglyceride metabolism. PNAS 2013, 110:4810-4815.
39. Nov O, Shapiro H, Ovadia H, Tarnovscki T, Dvir I, Shemesh E, Kovsan J, Shelef I, Carmi Y, Voronov E, Apte RN, Lewis E, Haim Y, Konrad D, Bashan N, Rudich A: Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS ONE 2013, 8:e53626.
40. Bruun JM, Stallknecht B, Helge JW, Richelsen B: Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 2007, 157:465-471.
41. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D: Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002, 87:3864-3866.
42. Membrez M, Ammon-Zufferey C, Philippe D, Aprikian O, Monnard I, MacK, Darimont C: Interleukin-18 protein level is upregulated in adipose tissue of obese mice. Obesity 2009, 17:393-395.
43. Wang H-N, Wang Y-R, Liu G-Q, Liu Z, Wu P-X, Wei X-L, Hong T-P: Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol 2008, 14:7240-7246.
44. Paschos P, Paletas K: Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13:9-19.
45. Finotto S, Siebler J, Hausding M, Schipp M, Wirtz S, Klein S, Protschka M, Doganci A, Lehr HA, Trautwein C, Khosravi-Far R, Strand D, Lohse A, Galle PR, Blessing M, Neurath MF, Khosravi-Fahr R: Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut 2004, 53:392-400.